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MicroRNAs (miRNAs) are short, noncoding RNA mol-
ecules that regulate the expression of a number of
genes involved in cancer; therefore, they offer great
diagnostic and therapeutic targets. We have developed
doxorubicin-resistant and -sensitive metastatic human
breast cancer cell lines (MDA-MB-231) to study the
chemoresistant mechanisms regulated by miRNAs. We
found that doxorubicin localized exclusively to the
cytoplasm and was unable to reach the nuclei of re-
sistant tumor cells because of the increased nuclear
expression of MDR1/P-glycoprotein (P-gp). AnmiRNA
array between doxorubicin-sensitive and -resistant
breast cancer cells showed that reduced expression of
miR-298 in doxorubicin-resistant human breast can-
cer cells was associated with increased expression of
P-gp. In a transient transfection experiment, miR-298
directly bound to the MDR1 3= untranslated region
and regulated the expression of firefly luciferase re-
porter in a dose-dependent manner. Overexpression
of miR-298 down-regulated P-gp expression, increas-
ing nuclear accumulation of doxorubicin and cytotox-
icity in doxorubicin-resistant breast cancer cells. Fur-
thermore, down-regulation of miR-298 increased P-gp
expression and induced doxorubicin resistance in
sensitive breast cancer cells. In summary, these re-
sults suggest that miR-298 directly modulates P-gp ex-
pression and is associated with the chemoresistant
mechanisms of metastatic human breast cancer.
Therefore, miR-298 has diagnostic and therapeutic
potential for predicting doxorubicin chemoresistance
in human breast cancer. (Am J Pathol 2012, 180:
2490–2503; http://dx.doi.org/10.1016/j.ajpath.2012.02.024)
2490A number of chemotherapy regimens have been used to
treat metastatic breast cancer in humans. The success of
treating breast cancer by chemotherapy is hampered by
the development of multidrug resistance (MDR) of cancer
cells.1–3 MDR of cancer cell occurs because of the over-
expression of one or more of the ATP binding cassette
(ABC) transporters.4,5 There are three well-characterized
transporters, ABCB1 (MDR-1/P-gp), ABCC1 (MRP-1), and
ABCG2 (BCRP), associated with the chemoresistance of
breast cancer.6–10 The P-glycoprotein (P-gp) overexpres-
sion in breast cancer cells has been found to be strongly
associated with chemoresistant mechanisms of a variety of
drugs.11–13 P-gp is a 170-kDa transmembrane glycoprotein
that acts as an energy-dependent efflux transporter that
enhances drug efflux from the nucleus or prevents entry of
drugs to the nucleus, thereby decreasing cytotoxicity of
anticancer drugs.12–14 A number of mechanisms have been
proposed to explain the transcriptional activation of the
P-gp gene (ABCB1) in cancer cells.15–18 Studies indicate
that increased resistance of chemotherapeutic agents is
also associated with epigenetic alterations, including DNA
methylation and histone modifications.19–21 The precise
cellular and molecular mechanisms underlying the in-
creased MDR1 gene expression is not clear.
New evidence indicates that changes in gene expression
associated with cell proliferation, apoptosis, signaling, and
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sion of cellular microRNAs (miRNAs). miRNAs are small
non–protein-coding RNAs that regulate gene expression
through base pairing with target mRNAs, resulting in trans-
lation inhibition or mRNA cleavage.22 miRNAs are pro-
duced through a series of steps that are initially generated
in the nucleus where primary miRNAs are transcribed by
RNA polymerase II. The primary transcripts are subse-
quently processed to shorter (70 to 85 nt) precursor (pre-)
miRNA mediated by an RNase III enzyme called Drosha,
and its cofactor DGCR8.23–25 Subsequently, pre-miRNAs
are exported to the cytoplasm by exportin 5 and then
cleaved by Dicer, another RNase III enzyme, to produce a
22-nt double-strandedmiRNA duplex.26–30 The strand con-
taining less stable hydrogen bonding at its 5= end is the
mature miRNA and is integrated into the RNA-induced si-
lencing complex, whereas the other strand is degraded.27
To understand the role of miRNAs in the regulation of
MDR of breast cancer cells, we developed doxorubicin-
sensitive and -resistant metastatic human breast cancer
cells (MDA-MB-231). We showed that high-level expression
of P-gp leads to the impaired nuclear translocation of doxo-
rubicin and the doxorubicin chemoresistance of MDA-MB-
231. To study the role of miRNA involvement in the doxoru-
bicin chemoresistancemechanism, we performed amiRNA
array between the doxorubicin-sensitive and -resistant met-
astatic breast cancer cells. We found significant up-regula-
tion and down-regulation of miRNAs in the doxorubicin-
resistant human breast cancer cells compared with the
sensitive cells. We have determined that miR-298 is down-
regulated significantly in the doxorubicin-resistant MDA-
MB-231 cells compared with the doxorubicin-sensitive
MDA-MB-231 cells. Using the miRNA database, we found
that human miR-298 targeted to the 3= untranslated region
(UTR) of the human P-gp mRNA. Because the role of
miRNA-mediated development of resistance to the chemo-
therapeutic drug is largely unexplored, our study provides
the evidence to suggest that the impaired processing of miR-
298 because of low expression of Dicer enzyme is associated
with an increased expression of P-gp and contributes to the
doxorubicin resistance in breast cancer cells. This interaction
may have an important functional consequence in the forma-
tion of cancer cell resistance to a variety of chemotherapeutic
drugs used in the treatment of breast cancer.
Materials and Methods
Cell Culture and Reagents
The MDA-MB-231 and MCF-7 human breast cancer cell
lines were obtained from ATCC (Manassas, VA). These
two cell lines were cultured in high-glucose Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS), sodium pyruvate, nones-
sential amino acids, and 1% penicillin and streptomycin
(Invitrogen, Grand Island, NY) at 37°C in a humidified
atmosphere with 5% CO2 and 95% air. Doxorubicin
(Adriamycin) was purchased from Sigma Chemical Co.
(St. Louis, MO). A stock solution of doxorubicin (1 mg/mL
1.8 mmol/L) was prepared in distilled water. MDA-MB-231 cells were continuously cultured in growth medium in
the presence of 0.18 mol/L doxorubicin. After several
passages, clones that grew in the presence of doxorubicin
were selected as drug-resistant cancer (MDA-MB-231-R)
cells. The MDA-MB-231-R cells had been cultured for 6
months in the growth medium supplemented with doxoru-
bicin to assure that they were truly resistant to doxorubicin.
With the use of a limiting dilution method, MDA-MB-231
cells showing increased doxorubicin-mediated cytotoxicity
were isolated. Clones showing the highest cytotoxicity
in the MTT assay were selected as doxorubicin-sensi-
tive MDA-MB-231 (MDA-MB-231-S) cells. Doxorubicin-
resistant MCF-7 cells (MCF-7-Dox) were obtained from the
laboratory of Debasis Mondal (Tulane University School of
Medicine, Tulane, LA) and were cultured in high-glucose
DMEM supplemented with 10% FBS, sodium pyruvate,
nonessential amino acid, 1% penicillin/streptomycin (Invit-
rogen), and 1 mol/L insulin (Human Recombination, zinc
solution; Invitrogen).
Cell Proliferation
Cell viability after doxorubicin treatment was measured
by the MTT assay. The assay uses a tetrazolium com-
pound (3-[4,5-dimethylthiazol-2-yl]2,5-diphenyl tetrazo-
lium bromide; Sigma-Aldrich, St. Louis, MO), which was
reduced to formazan intracellularly by the mitochondrial
dehydrogenase enzyme. The conversion of tetrazolium
into purple formazan by metabolically active cells indi-
cates the extent of cell viability. The viability of tumor cells
was measured by the quantification of formazan dye by
the colorimetric method. The MDA-MB-231 or MCF-dox
cells were seeded on 24-well plates at a density of 2 
104 cells/well in DMEM with 10% FBS and allowed to ad-
here at 37°C overnight. After 24 hours, culture medium was
replaced and treated with four different concentrations
(0.09, 0.18, 0.36, and 0.72 mol/L) of doxorubicin. After 48
hours of incubation, cells were stained with 100 L (5
mg/mL of PBS) of MTT solution along with 900 L of growth
medium added in each well. Cells were incubated at 37°C
for 3 hours. Then, the tumor cells were washed in PBS and
were solubilized with 1 mL of MTT solubilization buffer (an-
hydrous isopropanol containing 10% Triton X-100, 0.1N
HCl) for 5 minutes. Absorbance of converted dye was mea-
sured in a spectrophotometer (Beckman Du 530, Life Sci-
ence UV/Vis spectrophotometer; Beckman Coulter, Inc,
Schaumburg, IL) at 570 nm. The percentage of cell viability
was determined by comparison with untreated cells as con-
trols.
Flow Cytometry
MDA-MB-231-S and MDA-MB-231-R cells (1  105)
were seeded into 100-mm plates in DMEM with 10%
FBS at 37°C overnight. On the next day, the medium
was aspirated and replaced with 10 mL of fresh media
containing 0.18 mol/L doxorubicin. After 24 hours of
treatment, cells were washed with PBS and trypsinized
with 0.05% Trypsin-EDTA (Invitrogen). The cells were
fixed in 70% ethanol in PBS and incubated for 2 hours
on ice. The fixed cells were subsequently washed
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5 minutes. The cells were resuspended in a commer-
cially available propidium iodide staining solution (BD
Pharmingen, San Diego, CA). Cells were incubated in
the dark for 30 minutes at room temperature. The cell
cycle analysis was performed with the use of 2  104
cells by a flow cytometer (BD LSR II; BD Biosciences,
San Jose, CA). The percentage of tumor cells present
in the G1, S, and G2 phases of the cell cycle was
analyzed with the computer software (Modfit LT 3.0;
Verity Software House, Topsham, ME).
Western Blot Analysis
Briefly, the cells were cultured in a 6-well plate and lysed
with 200 L of RIPA lysis buffer. Total protein in the lysate
was quantified by Bradford protein assay (Bio-Rad Lab-
oratories Inc., Hercules, CA). Approximately 10 g of
protein from each sample was mixed in 4 SDS-loading
buffer. Proteins were separated by NuPAGE 12% gel and
then transferred onto a nitrocellulose membrane (GE
Healthcare, Buckinghamshire, UK). The membrane was
blocked with 5% fat-free milk powder in 50 mmol/L Tris-
buffered saline (TBS) pH 7.6 with 0.1% Tween-20 (TBS-
Tw20) at room temperature for 1 hour. The membrane was
washed three times and incubated overnight at 4°C with
either the mouse monoclonal antibody to P-gp at 1:500
dilution (C219; AbCam, Inc., Cambridge, MA) or the rabbit
monoclonal anti--actin clone (Cell Signaling Technologies,
Danvers, MA) at 1:1000 dilution in TBS-Tw20 containing 5%
fat-free milk powder. After this step, the membrane was
washed three times with TBS-Tw20 and reacted for 1 hour
with the secondary antibody, anti-mouse or anti-rabbit IgG
(Cell Signaling Technologies) that was conjugated with HRP
at a dilution of 1:2000. The bound antibodies were detected
with the use of ECL Plus Western Blotting Detection system
(GE Healthcare), and the chemiluminiscent signals were
detected with the use of high-performance chemilumines-
cence film (GE Healthcare).
Immunocytochemistry
The MDA-MB-231-S and MDA-MB-231-R cells were cul-
tured overnight on the chamber slides. The next day, slides
were fixed with chilled acetone and treated with 1 mL of
blocking reagent (Background Sniper; Biocare Medical,
Concord, CA) for 10 minutes at room temperature. The
slides were then incubated with a primary mouse monoclo-
nal antibody C219 at 1:250 dilution (AbCam, Inc.) at room
temperature for 1 hour, followed by a secondary reagent
MACH 4 mouse probe (Biocare Medical) for 10 minutes,
then a tertiary reagent Mach 4 HRP polymer (Biocare Med-
ical) for 20 minutes. At the final step, the slides were coun-
terstained with hematoxylin and bluing.
miRNA Array
miRNA was extracted from MDA-MB-231-S and MDA-
MB-231-R cells with the use of the Purelink miRNA Isola-
tion Kit (Invitrogen) according to the manufacturer’s in-
structions. To compare the profiles of miRNA expressionin these samples, we used the miRCURY LNA miRNA
Array, 6th Generation - Human, Mouse & Rat (Exiqon Inc.,
Woburn, MA). This array platform allows a simultaneous
screening of the expression of all known human, mouse,
and rat miRNA molecules known to date. Samples ex-
tracted from the control (S) cells were labeled with Cy3,
and those from the experimental (R) cells were labeled
with cyanine 5, using the mercury LNA miRNA labeling kit
(Exiqon Inc.). Cyanine-labeled samples were then mixed
together in equivalent concentrations and cohybridized
to the array overnight at 55°C in a rotary chamber. Slides
were scanned on a dual confocal Axon GenePix 4000B
scanner (Molecular Devices, Sunnyvale, CA) with the use
of GenePix version 6.2 software, and raw data were ex-
tracted. A stringent set of criteria was applied to remove
background and highly variable data from consideration.
The remaining data were log2 transformed and normalized,
using Locally Weighted Scatter-plot Smoothing in Spotfire
S, to remove intensity-specific bias. miRNAs were consid-
ered to be differentially expressed if they exhibited a twofold
perturbation in expression magnitude.
Northern Blot Analysis
Expression miRNA in the doxorubicin-sensitive and -re-
sistant breast cancer cells was examined by Northern
blot analysis with the use of a miRNA Northern Blot Assay
Kit (Signosis BioSignal Capture, Sunnyvale, CA). Briefly,
total RNA was extracted from MDA-MB-231-S and MDA-
MB-231-R cells with the use of the Purelink total RNA
purification system (Invitrogen). Cellular RNA (5 g)
mixed with 3 L of RNA loading buffer was heated at
70°C for 5 minutes and chilled on ice. RNA samples in a
10-L volume were loaded onto a 15% urea-polyacryl-
amide gel at 60 V in 0.5 TBE buffer until bromophenol
blue dye reached approximately 3 cm away from the
bottom of the gel. RNAs were transferred to a nylon
membrane (Signosis BioSignal Capture) with the use of
XCell SureLock Electrophoresis (Invitrogen), immobilized
with Stratagene UV cross-linker, and dried at 42°C for 15
minutes. The membrane was transferred into a hybridiza-
tion tube, soaked with distilled H2O, and incubated with 4
mL of prewarmed (42°C) hybridization buffer then rotated
for 30 minutes at 42°C. The membrane was replaced with
4 mL of fresh hybridization buffer along with 10 mL of
biotin-labeled miRNA probe and rotated at 42°C over-
night. The membrane was removed to an empty con-
tainer and rinsed with 10 mL of 1 detection wash buffer
and then blocked with 15 mL of blocking buffer for 30
minutes at room temperature with moderate shaking.
Then the membrane was incubated with 1 mL of the 1
blocking buffer containing 15 mL of streptavidin-HRP
conjugate for 45 minutes at room temperature. Then the
blocking buffer was removed, and the membrane was
washed three times at room temperature with 15 mL of
1 detection washing buffer for 10 minutes each wash.
The membrane was incubated with 2 mL of Tris-Buffer pH
7.4 with 200 L of substrate A and B at room temperature
for 5 minutes. After this step, excess substrate was re-
moved by gently applying pressure over the top sheet
with the use of a paper towel. The membrane was ex-
miR-298 Regulates MDR1 2493
AJP June 2012, Vol. 180, No. 6posed with Amersham Hyperfilm ECL (GE Healthcare).
Membranes were stripped and reprobed to assess other
miRNAs.
Plasmid Constructs
The 3= UTR of P-gp gene (ABCB1) corresponding to 4262
to 4872 nt (610 bp; Accession no. NM-000927) was
cloned into pMirTarget vector by SgfI and MluI restriction
sites called pMirTarget-MDR1-3= UTR (SC208086; Ori-
gene Technology, Inc., Rockville, MD). Two different con-
trol plasmids with deletion of miR-298 and miR-1253
binding sites were prepared by overlapping PCR and
cloned into pMirTarget vector with the use of the unique
AscI (GGCGCGCC) and MluI (ACGCGT) restriction sites
(Origene Technology, Inc.). The 571-bp DNA fragment
with 25-nt deletion in the miR-298 binding site was am-
plified by overlapping PCR of Fragment 1 (F1) and Frag-
ment 2 (F2). The F1 (411 bp) was PCR amplified with the
use of the sense primer (P1), 5=-TCGGGCGCGC-
CACTCTGACTGTATGAGATGTT-3=, and antisense
primer (P2), 5=-AAAGAAAACTTTTTTAAAATTGAGAGAA-
GATATA-3=, and wild-type MDR1/3= UTR plasmid as a
template. The F2 (160 bp) was amplified from MDR1/3=
UTR plasmid with the use of sense primer (P3), 5=-
TATATCTTCTCTCAATTTTAAAAAAGTTTTCTTT-3=, and
antisense primer (P4), 5=-GGCACGCGTGAATCAGCAG-
GATCAAGTCCAAGAAGAATG-3=. AscI site was added
to the outer sense primer, and MluI site was added to the
outer antisense primer. The PCR-amplified DNA was di-
gested with AscI and MluI restriction endonucleases and
cloned into the downstream of the firefly luciferase re-
porter gene in the AscI/MluI cloning sites of pMirTarget
vector. The sequence of the recombinant clones was
confirmed by DNA sequencing and was called pMirTar-
get-MDR1-3= UTR with deletion of miR-298. The PCR
amplification cycles were 94°C for 5 minutes, then 33
cycles at 94°C for 30 seconds, 55°C for 30 second, 72°C
for 1 minute, followed by 72°C for 10 minutes. Likewise,
the 572-bp DNA fragment with 24-nt deletion in the miR-
1253 binding site was amplified by overlapping PCR of
Fragment 3 (F3) and Fragment 4 (F4). Briefly, the first
381-bp F3 was amplified with the use of sense primer
(P1) and antisense primer (P5), 5=-CTACAATATTCCAAT-
TGGGATAAGATGACTCCAG-3=, using the wild-type
MDR1/3= UTR plasmid as a template. The second 191-bp
F4 was amplified with the use of the sense primer (P6),
5=-CTGGAGTCATCTTGTCCCAATTGGAATATTGTAG-3=,
and antisense primer (P4) with the use of the wild-type
MDR1/3= UTR plasmid as a template. AscI site was
added to the outer sense primer (P1), and Mlu I site was
added to the outer antisense primer (P4) so that the
recombinant DNA fragment can be cloned into pMirTar-
get vector with the use of the unique restriction sites. The
PCR amplification cycles are the same as above. The
sequence of the recombinant clones was confirmed by
DNA sequencing and is called pMirTarget-MDR1-3= UTR
with deletion of miR-1253.Luciferase Reporter Assay for MDR1-3= UTR
The MDA-MB-231-R or MCF-7-Dox cells were seeded in
24-well plates and were transfected with 25 ng of the firefly
luciferase MDR1-3= UTR-reporter vector (PS100062; Ori-
gene Technology, Inc.) along with the miR-298, miR-1253
mimic (Ambion Pre-miR miRNA Precursor; Ambion by
Life Technologies, Carlsbad, CA), or inhibitor (Ambion
Anti-miR miRNA Inhibitor; Ambion by Life Technologies)
with the use of LipofectAMINE 2000 reagent according to
the manufacturer’s protocol (Invitrogen). After transfec-
tion for 24 hours, cells were lysed with a 1 Passive Lysis
Buffer, and the activity of luciferase was assayed with the
firefly luciferase reporter assay system (Promega, Valen-
cia, CA) according to the manufacturer’s instructions.
The values were normalized by total protein of cell lysate.
The efficiency of lipofectamine transfection to breast can-
cer cells was determined by fluorescence microscopy
with the use of Cy3-labeled RNA oligonucleotides.
Doxorubicin Nuclear Accumulation
Doxorubicin accumulation was assayed by a method de-
scribed previously.31 Briefly, MDA-MB-231-R cells or
MDA-MB-231-S cells were transfected with the miRNAs
mimics or miR-298 inhibitor with the use of lipofectamine.
After 24 hours, transfected cells were incubated over-
night with doxorubicin (0.72 mol/L). Then cells were
washed thrice with PBS, fixed with methanol, and ob-
served under a fluorescence microscope (1  70; Olym-
pus, Tokyo, Japan).
Results
Impaired Nuclear Translocation of Doxorubicin
in MDA-MB-231-R Cells Occurs Because of the
Increased Expression of P-gp
The antitumor effect of doxorubicin on the MDA-MB-
231-R and MDA-MB-231-S breast cancer cells was
investigated by MTT assay. A significant difference in
the doxorubicin-mediated cytotoxicity between the
drug-resistant (MDA-MB-231-R) and drug-sensitive
(MDA-MB-231-S) breast cancer cell line was observed.
The doxorubicin at a concentration of 0.36 mol/L
leads to a 20% growth arrest in the MDA-MB-231-S
cells, whereas only 2% to 4% growth arrest was seen
with the use of the MDA-MB-231-R cells (Figure 1A).
The cellular cytotoxicity of doxorubicin (0.36 mol/L)
with the use of the two cell lines was also measured by
MTT assay for 24, 48, and 72 hours, which shows a
time-dependent increase in cytotoxicity (Figure 1B).
The ability of doxorubicin to induce cell cycle arrest
and apoptosis between the MDA-MB-231-R and MDA-
MB-231-S cell lines was measured by flow cytometry
(Figure 1C). These results indicate that doxorubicin
treatment leads to G2/M growth arrest in the majority of
cells (89.59%) and that only 10% of cells stay in the S
phase of cell cycle in MDA-MB-231-S, whereas only
16% G2/M growth arrest was seen in MDA-MB-231-R.
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cancer model, we have shown that doxorubicin treat-
ment induced apoptotic cell death because of DNA
break in most of the drug-sensitive breast cancer
cells,31 whereas in the resistant breast cancer cell line
no TUNEL-positive cells were present. To understand
the mechanism of doxorubicin resistance, the cellular
uptake of doxorubicin between the MDA-MB-231-S
and MDA-MB-231-R cells was compared by flow cy-
Figure 2. Impaired uptake and nuclear translocation of doxorubicin in the M
plate were treated with doxorubicin (0.18 mol/L) for 24 hours. Cells wer
cytometric analyses of MDA-MB-231-S and MDA-MB-231-R cells show the in
in the doxorubicin-treated cells compared with the untreated cells. B: Fluore
hours after doxorubicin treatment. The left panels show that doxorubicin lo
doxorubicin fluorescence was observed in the cytoplasm of MDA-MB-231-R cells.
panels are the composite image with Hoechst nuclear staining (original magnificattometry. MDA-MB-231-S and MDA-MB-231-R cells
were treated with doxorubicin (0.18 mol/L). After 24
hours, the intracellular doxorubicin fluorescence was
measured by flow cytometry (Figure 2A). The results
indicate that a shift in the fluorescence peak because
of intracellular doxorubicin between the MDA-MB-
231-S and MDA-MB-231-R cells indicates that doxoru-
bicin is able to cross the cell membrane. The fluores-
cence microscopic results indicate that most of the
-231-R cells. MDA-MB-231-S and MDA-MB-231-R cells cultured in a 100-mm
d and analyzed for cellular uptake and fluorescence microscopy. A: Flow
ar uptake of doxorubicin (DOXO). There is a shift in the fluorescence peak
microscopy images show the MDA-MB-231-S and MDA-MB-231-R cells at 24
in the nucleus of MDA-MB-231-S cells. The right panels show that most of
Figure 1. Characterization of the MDA-MB-
231-R and MDA-MB-231-S cell lines. A: MTT as-
say showing the cytotoxicity of the two cell lines
on dose-dependent treatment of doxorubicin
(0.09 to 0.72 mol/L). Cells were treated with
different concentrations of doxorubicin, and af-
ter 48 hours of treatment doxorubicin-mediated
cytotoxicity between the cells was determined
by MTT assay. B: MTT assay showing cytotoxic-
ity of MDA-MB-231-S and MDA-MB-231-R cell
lines at 0, 24, 48, and 72 hours after doxorubicin
treatment (0.36 mol/L). C: Cell cycle analysis of
MDA-MB-231-S and MDA-MB-231-R cells after
doxorubicin (DOXO) treatment. Cells were cul-
tured in 100-mm tissue culture dishes and
treated with doxorubicin (0.18 mol/L) for 48
hours. Cells were harvested by trypsin-EDTA,
treated with propidium iodide, and analyzed by
flow cytometry. The left panels show the cell
cycle profile of doxorubicin-sensitive (MDA-MB-
231-S) cells in the absence and the presence of
the doxorubicin. The right panels show cell
cycle profile of doxorubicin-resistant (MDA-MB-
231-R) cells in the absence and the presence of
doxorubicin. The percentage of cells in G1, G2,
and S phases of cell cycle is listed for each
analysis. Data are expressed as mean  SD (A
and B).DA-MB
e washe
tracellul
scence
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ion, 20).
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MB-231-S cells. In the MDA-MB-231-R cells, doxorubi-
cin is unable to reach the nucleus and remained ex-
clusively in the cytoplasm (Figure 2B). To examine
whether expression of different drug efflux proteins
could correlate with the impaired nuclear uptake of
Figure 3. Increased expression of P-gp in doxorubicin-resistant breast c
Immunocytochemical staining shows the expression of three different dru
cells with the use of specific monoclonal antibodies against MDR1, MRP
seen only in the MDA-MB-231-R cells. The expression of P-gp in MDA-MB
was negative (original magnification, 20). B: Western blot analysis conf
with the use of MDR1, MRP1, and BCRP antibodies. Antibody to -tubulin
of doxorubicin. MDA-MB-231-R cells were pretreated with 20 mol/L
doxorubicin for 48 hours, and cytotoxicity was measured by MTT assay. D
MDA-MB-231-R cells in culture were treated with 20 mol/L verapamil fo
translocation was examined under a fluorescence microscope. The left p
without verapamil treatment. The right panel shows the nuclear tran
verapamil. Original magnification, 20. E: Treatment with the second-gen
in MDA-MB-231-R cells by Western blot analysis in a time-dependent man
the doxorubicin cytotoxicity of MDA-MB-231-R cells. Data are expresseddoxorubicin in MDA-MB-231-R cells, the expression ofP-gp, MRP, and BCRP between the MDA-MB-231-S
and MDA-MB-231-R cells was examined by immuno-
cytochemical staining (Figure 3A). To support the im-
munocytochemistry results, the expression of P-gp,
MRP1, and BCRP1 was also confirmed by Western blot
analysis (Figure 3B). We observed a high-level nuclear
ll line and inhibition of its expression improved cellular cytotoxicity. A:
pumps (MDR1, MRP1, and BCRP) in MDA-MB-231-S and MDA-MB-231-R
CRP. Strong cytoplasmic and nuclear stainings of P-gp expression were
cells was undetectable. The expression of MRP1 and BCRP1 in both cells
expression of these proteins in MDA-MB-231-S and MDA-MB-231-R cells
d as loading control. C: Verapamil pretreatment improves the cytotoxicity
mil for 2 hours and then treated with an increasing concentration of
amil pretreatment facilitates nuclear translocation of doxorubicin (Doxo).
rs and then treated with doxorubicin (0.72 mol/L) for 24 hours. Nuclear
ows the nuclear translocation of doxorubicin in the MDA-MB-231-R cells
n of doxorubicin (red) in the MDA-MB-231-R cells in the presence of
P-gp inhibitor (PSC833) at 10 mol/L concentration reduces its expression
to 48 hours). F: MTT assay shows that pretreatment with PSC833 improves
n  SD (C and F).ancer ce
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Both cell lines showed negative expression of MRP and
BCRP by immunocytochemical staining and Western
blot analysis. To verify the role of increased expression
of P-gp in MDA-MB-231-R cells, experiments were per-
formed to examine whether inhibiting the expression of
P-gp in the MDA-MB-231-R cells could increase the
nuclear translocation of doxorubicin and cytotoxicity.
We used verapamil, a first-generation MDR efflux
pump inhibitor.32 The MDA-MB-231-R cells in culture
were pretreated with verapamil at a concentration of 20
mol/L for 2 hours, the cells were then treated with
doxorubicin at an increasing concentration (0.09, 0.18,
0.36, and 0.72 mol/L), and MTT assay results indicate
that pretreatment with verapamil improved doxorubicin
toxicity of MDA-MB-231-R cells after 48 hours (Figure
3C). The improved cytotoxicity was due to increased
nuclear translocation of doxorubicin seen under a flu-
orescence microscope (Figure 3D). We also used a
second-generation P-gp inhibitor (PSC833) to examine
whether it could improve doxorubicin-mediated cyto-
toxicity in MDA-MB-231-R cells. PSC833 is well known
Figure 4. Differential expression of miRNAs between MDA-MB-231-S and
miRNA levels (normalized median values) in MDA-MB-231-S versus MDA-M
down-regulated in the MDA-MB-231-R cell line relative to the MDA-MB-231-S
MDA-MB-231-S. C: Detection of both pre-miRNA and mature miR-298 in MD
total RNA isolated from MDA-MB-231-S and MDA-MB-231-R cells was proces
miR-338, miR-451, and miR-U6. Most of miR-298 in MDA-MB-231-R cells t
miRNA-298 can be detected in MDA-MB-231-S cells. We could not detect o
The miR-U6 used as a control was detected in both the cells; because membr
arrows indicate the different forms of miRNA.D:Western blot analysis for Drosha, Di
The expression of Dicer is low in MDA-MB-231-R cells compared with MDA-MB-23as a nonimmunosuppressant cyclosporine analog that
functionally inhibits P-gp.33 Western blot analysis
showed that pretreatment of MDA-MB-231-R cells with
PSC833 at a concentration of 10 mol/L after 24 hours
inhibited the expression of P-gp (Figure 3E). Treatment
of MDA-MB-231-R cells with PSC833 followed by doxo-
rubicin improved the cytotoxicity by MTT assay (Figure
3F). These results indicate that P-gp expression is
partly responsible for impaired nuclear translocation of
doxorubicin and cytotoxicity.
Down-Regulation of miR-298 in
MDA-MB-231-R Cells
Because the miRNAs are an important modulator of cancer
cell signaling and chemotherapy response, we generated
an miRNA profile between MDA-MB-231-S and MDA-MB-
231-R cells. We found a significant up-regulation and down-
regulation of miRNAs in MDA-MB-231-R cells compared
with MDA-MB-231-S cells. Among the list, we only show 10
miRNAs whose expression significantly changed between
B-231-R cells by miRNA array analysis. Data are shown as fold changes of
cells. The relative levels were normalized to U6snRNA. A: miRNAs that are
: miRNAs that are up-regulated in the MDA-MB-231-R cell line relative to the
1-S and MDA-MB-231-R cells by Northern blot analyses. Five micrograms of
Northern blot analysis with the use of probes specific to miR-298, miR-1253,
e pre-miRNA remained in the unprocessed form (top band). Only mature
NAs in MDA-MB-231-S and MDA-MB-231-R cells by Northern blot analysis.
re stripped and reprobed, the control is identical for each miRNA tested. TheMDA-M
B-231-R
cells. B
A-MB-23
sed for
hat wer
ther miR
anes wecer, and Argonaute 2 expression in MDA-MB-231-S and MDA-MB-231-R cells.
1-S cells. -actin was used as a loading control.
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predicted target of miR-298 and showed down-regulated
expression in MDA-MB-231-R cells. Northern blot analysis
was used to show the difference of miR-298 expression
between MDA-MB-231-S and MDA-MB-231-R cells. The
results of this experiment indicate that mature miR-298 and
its precursor are highly expressed in MDA-MB-231-S cells
compared with MDA-MB-231-R cells (Figure 4C). We also
found that the processing of miR-298 was blocked in MDA-
MB-231-R cells becausewe could detect only the precursor
miRNA but no mature miRNA. Web-based miRNA search
(http://www.microRNA.org, 2008 release, last accessedOc-
tober 1, 2009) as well as published papers indicate that
miR-1253, miR-451, miR-338, and miR-27a regulate the ex-
pression of P-gp by binding to the 3= UTR of the MDR1
gene.34–36 We could not detect any of these miRNAs levels
in MDA-MB-231-R cells by Northern blot analysis. To show
the cause of profound alternations in the miRNA profile in
the MDA-MB-231-R cells, we decided to analyze the levels
of the miRNA processing enzymes, Drosha, Dicer, and Ar-
gonaute 2, by Western blot analysis. Drosha is the core
nuclease that executes the initiation step of miRNAprocess-
ing in the nucleus27 and cleaves double-strand primary-
Figure 5. Schematic diagram showing the location and binding sites of
UTR-luciferase plasmid construct used in this study. A: Exact nucleotide (nt) location
B: Deletion of miR-298 binding site in 3= UTR region of P-gp mRNA. C: Deletion ofmiRNA (1-kb nt) to produce a stem-loop precursor mole-
cule (pre-miRNA), 70 nt in length. Dicer, a member of the
RNase III superfamily of bidentate nuclease, mediates the
latter step. After the pre-miRNA is transported to the cyto-
plasm, the pre-miRNA undergoes its final processing step,
which involves cleavage by Dicer.28 The involvement of
Dicer in MDA-MB-231-R cells was examined. Argonaute
protein 2 was associated with small RNAs that guidemiRNA
degradation, translational repression, or a combination of
both.28 Western blot analysis showed a strong down-regu-
lation of Dicer levels in MDA-MB-231-R cells, but no differ-
ent expression of Drosha and Argonaute in MDA-MB-231-S
and MDA-MB-231-R cells was observed (Figure 4D). The
significantly decreased level of Dicer may explain the po-
tential reason for the dysregulated expression of miRNAs in
the MDA-MB-231-R cells.
MmiR-298 Targets the 3= UTR of P-gp mRNA
For investigating the role of miRNAs in the P-gp regula-
tion, we used a computational analysis of the 3= UTR of
MDR1 that found a putative binding site for miR-298,
miR-1253.34 Mature sequence of miR-298 (5=-AGCA-
, miR-1253 in the 3= UTR region of p-gp mRNA of pmiRTarget-MDR1-3=miR-298
of miR-298 and miR-1253 binding sites in the 3= UTR region of P-gp mRNA.
miR-1253 binding site in 3= UTR region of P-gp mRNA.
MirTarg
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AJP June 2012, Vol. 180, No. 6GAAGCAGGGAGGUUCUCCCA-3=) matched MDR1
mRNA at 4681 to 4705 nt, and miR-1253 (5=-AGAGAA-
GAAGAUCAGCCUGCA-3=) matched at 4660 to 4681
nt (Figure 5A). To understand whether MDR1 is func-
tionally targeted by miR-298 and miR-1253, 3= UTR of
MDR1 with miR-298 and miR-1253 complimentary site
was cloned into pMirTarget, the clone vector for all 3=
UTRs for miRNA target validation. Two plasmid con-
structs with a deletion of each miRNA (miR-298 or
miR-1253) sequences was prepared and used as a
control in our assays (Figure 5, B and C). With the use
of a transient transfection, we found that miR-298
mimic inhibited the firefly luciferase expression only on
the wild-type pMirTarget-MDR1-3= UTR construct with
the miR-298 binding site in a concentration-dependent
manner (Figure 6A). The luciferase expression of pMir-
Target-MDR1-3= UTR without the miR-298 binding sites
did not change after mimic transfection and remained
comparable with the untreated samples. Likewise, we
observed that miR-1253 mimic showed a dose-depen-
dent decrease in the luciferase expression of the pMir-
Target-MDR1-3= UTR construct by transient transfec-
tion. Both the miR-1253 deletion plasmid transfection
and the untreated samples show similar readings, in-
dicating that the miR-1253 did not inhibit luciferase
expression (Figure 6B).
Overexpression of miR-298 Down-Regulates P-gp
Expression and Nuclear Translocation of Doxorubicin
and Increases Doxorubicin Cytotoxicity
Western blot analysis and immunocytochemical stain-
ing found that MDA-MB-231-R cells exhibit a high ex-
pression of P-gp, compared with MDA-MB-231-S cells.
We used miRNA mimics to confirm that miR-298 alters
Figure 6. Effect of miRNA mimic transfection on the expression of MDR1-3
the expression of chimeric firefly luciferase on pmiRTarget-MDR1-3= UTR in a
luciferase of pMirTarget-vector or pMirTarget-MDR1-3= UTR with deletion of
MDR1-3= UTR dose-dependent manner but not the pMirTarget-vector and p
triplicated values  SD of the mean.the expression levels of P-gp in MDA-MB-231-R cells.MDA-MB-231-R cells were transfected with miR-298
and/or miR-1253 mimics by lipofectamine, and after 24
hours the level of P-gp expression in the presence and
absence of miRNA mimic was examined by Western
blot analysis. Results (Figure 7A) indicate that miR-298
and miR-1253 each treated either individually or in
combination inhibited the expression of P-gp. We then
examined whether inhibiting P-gp by miRNA mimics
could also increase cytotoxicity. Cells were transfected
overnight with miR-298 and/or miR-1253 into MDA-MB-
231-R cells and the next day treated with doxorubicin,
and cell viability was measured by MTT assay after 24
hours (Figure 7B). Because the impaired nuclear trans-
location was caused by the high-level expression of
P-gp, we examined whether transfection of the miRNA
mimics could improve the nuclear translocation of
doxorubicin in MDA-MB-231-R cells under fluores-
cence microscopy (Figure 7C). The results clearly
show that pretreatment with miR-298 and miR-1253
individually or in combination increased nuclear trans-
location of doxorubicin. The efficiency of miR transfec-
tion to breast cancer cells with the use of lipofectamine
was determined to be 100% with Cy3-labeled RNA
oligonucleotides (Figure 7D).
Down-Regulation of miR-298 in MDA-MB-231-
S Cells Induced Expression of P-gp and
Doxorubicin Chemoresistance
To assess the potential interaction between miR-298 and
P-gp expression in chemoresistance, we performed re-
verse experiments to determine whether the doxorubicin
chemoresistance can be restored by inducing the ex-
pression of P-gp in MDA-MB-231-S cells by down-regu-
lating the expression of miR-298 by transient transfection
himeric firefly luciferase in MDA-MB-231-R cells. A: miR-298 mimic inhibits
pendent manner. The same miR-298 did not regulate the expression of firefly
binding site. B: miR-1253 mimic also inhibits the expression of pMirTarget-
et-MDR1-3= UTR with deletion of miR-1253. Data are expressed as mean of= UTR c
dose-de
miR-298with miR-298 inhibitor. MDA-MB231-S cells were trans-
use of C
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P-gp was examined by Western blot analysis and lucif-
erase activity. We found that silencing miR-298 by selec-
tive inhibitor lead to a dose-dependent increase in the
activity of MDR-3= UTR luciferase activity in MDA-MB-
231-S cells but not in the controls (Figure 8A). MTT assay
was performed to determine whether down-regulation of
miR-298 could alter the doxorubicin cytotoxicity of MDA-
MB-231-S cells. MDA-MB-231-S cells were pretreated
with miR-298 inhibitor by lipofectamine for 48 hours, and
then cells were treated with an increasing concentration
of doxorubicin for 72 hours. Cytotoxicity was measured
by MTT assay (Figure 8B). The expression level of P-gp in
MDA-MB-231-S cells with or without transfection with
miR-298 inhibitor was examined by Western blot analysis
(Figure 8C). MDA-MB-231-S cells transfected with miR-
298 inhibitor showed impaired nuclear translocation of
doxorubicin compared with the untreated cells (Figure
8D). These analyses concluded that transfection with
miR-298 inhibitor in MDA-MB-231-S cells has made it
partially resistant to doxorubicin because of increased
Figure 7. Overexpression of miR-298 inhibits P-gp expression, increased
MDA-MB-231-R cells were transfected individually with miR-298, miR-1253,
MDA-MB-231-R cells was examined by Western blot analysis. P-gp expre
combination with miR-1253. B: MTT assay shows the doxorubicin cytotoxici
were transfected with miR-298 and miR-1253 singly and in combination. Afte
performed after 24 hours. Doxorubicin cytotoxicity of MDA-MB-231-R ce
combination. C: Fluorescence microscope images of doxorubicin nuclear tr
magnification, 20. The miR-298, miR-1253, and the combination treatme
Efficiency of lipofectamine transfection in MDA-MB-231-Dox cells with the
small-interfering RNA (original magnification, 20).P-gp expression.Overexpression of miR-298 Down-Regulates
P-gp Expression in MCF-7-Dox Cells
The role of miR-298 in regulating P-gp expression was
verified with another human breast cancer cell line
(MCF-7) resistant to doxorubicin. First, MTT assay was
performed to confirm the doxorubicin cytotoxicity be-
tween doxorubicin-sensitive and doxorubicin-resistant
MCF-7 breast cancer cells. MTT assay shows a signifi-
cant difference in the doxorubicin-mediated cytotoxicity
between the drug-resistant (MCF-7-Dox) and the parental
MCF-7 breast cancer cell line (Figure 9A). The doxorubi-
cin at a concentration of 2.88 mol/L leads to a 40%
growth arrest in the MCF-7 cells, whereas only 4% growth
arrest was seen with the MCF-7-Dox cells. The expres-
sion of P-gp between the MCF-7 and MCF-7-Dox cell
lines was analyzed by Western blot analysis (Figure 9B).
We observed a high-level expression of P-gp in MCF-7-
Dox cells but lower expression in MCF-7 cells. To confirm
that the miR-298 mimic also regulates P-gp luciferase re-
porter, MCF-7-Dox cells were cotransfected with pMirTar-
icity, and nuclear translocation of doxorubicin in MDA-MB-231-R cells. A:
mbination with the use of lipofectamine. After 24 hours, P-gp expression in
as inhibited in MDA-MB-231-R cells with miR-298 alone as well as in the
A-MB-231-R cells with or without miRNA transfection. MDA-MB-231-R cells
rs, cells were treated with doxorubicin (0.09 to 0.72 mol/L). MTT assay was
increased when transfected with miR-298 or miR-1253 individually or in
tion in MDA-MB-231-R cells without and with miRNA transfection. Original
ve the nuclear translocation of doxorubicin (fluorescence in nucleus). D:
y3-labeled oligonucleotide. Data are expressed as mean  SD (B). siRNA,cytotox
or in co
ssion w
ty in MD
r 24 hou
lls was
ansloca
nt improget-MDR1-3= UTR plasmid with or without miR-298 binding
microsc
agnifica
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was performed with the protein lysate of transfected cells.
We show that the miR-298 mimic inhibited the firefly lucifer-
ase expression only from pMirTarget-MDR1-3= UTR con-
struct in a concentration-dependent manner (Figure 9C).
No change in the luciferase expression was observed with
the use of pMirTarget-MDR1-3= UTR with deletion of the
miR-298 construct. The role of miR-1253 regulation of P-gp
luciferase expression in MCF-7-Dox cells was examined in
a transient transfection with miR-1253 mimic. We observed
that miR-1253 mimic also inhibited pMirTarget-MDR-3=UTR
luciferase expression by a concentration-dependent man-
ner to a lesser extent than miR-298. The luciferase expres-
sion of pMirTarget-MDR1-3= UTR without deletion of miR-
298 construct did not show inhibition and remained similar
to the untreated cells (Figure 9D). The results of MCF-7-Dox
experiments are identical to that with the MDA-MB-231-R
cells.
Discussion
miRNAs are short noncoding RNAs that posttranscrip-
Figure 8. Inhibition of miR-298 in MDA-MB-231-S cells increased the expres
inhibitor increased the expression of firefly luciferase gene containing the MDR-3
with total protein of the lysates. B: MTT assay shows the dose-dependent cytoto
miR-298 inhibitor. -Actin was used as a loading control. C: Inhibition of miR-29
manner as shown by Western blot analysis. D: Representative fluorescence
MDA-MB-231-S cells without and with miR-298 inhibitor (20 pmole) (original mtionally regulate expression of the target genes in a spe-cific tissue and/or cells at certain stages of their devel-
opment and/or cellular response to chemotherapy drugs.
More studies are now providing evidence to indicate that
they are important in regulating the expression of genes
involved in chemoresistant mechanisms in cancer treat-
ment.37 To address the chemoresistant mechanisms of
human breast cancer, we have developed chemoresis-
tant human breast cancer (MDA-MB-231) cells. We used
doxorubicin as a model drug that was marked as Adria-
mycin. We showed that the increased expression of P-gp
in MDA-MB-231-R cells is associated with impaired nu-
clear translocation of doxorubicin. In our experimental
model system, we show that doxorubicin was localized
mostly in the cytoplasm in MDA-MB-231-R cells, whereas
doxorubicin was efficiently localized to the nucleus in the
MDA-MB-231-S cells.
We show that doxorubicin chemoresistance of breast
cancer is due to deregulated expression of miRNA ex-
pression. This was supported by miRNA array data be-
tween MDA-MB-231-S and MDA-MB-231-R cells. The
miRNA data indicated that numerous miRNAs are up-
regulated and down-regulated in MDA-MB-231-R cells
-gp and induced doxorubicin resistance. A: Transient transfection of miR-298
quences in a dose-dependent manner (1.25 to 10 pmole). Data were normalized
doxorubicin (DOXO) in MDA-MB-231-S cells with or without transfection with
sion in MDA-MB-231-S cells increased expression of P-gp on a dose-dependent
opic pictures of the nuclear translocation of doxorubicin (0.72 mol/L) in
tion, 20). Data are expressed as mean  SD (A and B).sion of P
=UTR se
xicity of
8 exprescompared with MDA-MB-231-S cells. Because the in-
tion of
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of P-gp is the main mechanism involved in the doxorubi-
cin chemoresistance, we specifically found the down-
regulated expression of miRNAs that targeted to the P-gp
mRNA. We have identified miR-298 whose low-level ex-
pression is associated with increased P-gp expression.
Our results clearly show that the miR-298 expression is
altered in MDA-MB-231-R cells by Northern blot analysis.
Because of the low-level expression of Dicer, most of the
miR-298 remained in the unprocessed form. To confirm
the role of miR-298 in regulating the expression of P-gp,
we show that transfection of miR-298 mimic into MDA-
MB-231-R cells down-regulated expression of P-gp by
Western blot analysis as well as luciferase activity. We
also found that transfection of miR-298 mimic into MDA-
MB-231-R cells improved drug transport and nuclear
translocation of doxorubicin and cytotoxicity by MTT as-
say. The nuclear translocation of doxorubicin in the miR-
298-transfected cells is comparable with nontransfected
cells. Results of these functional studies support the role
of miR-298 in regulating the expression of P-gp. Taken
together these findings suggest that correcting the ex-
pression of miRNAs overcame drug resistance and im-
Figure 9. MCF-7-Dox cells show increased expression of P-gp, and miR-298
showing the doxorubicin (0.18 to 2.88 mol/L) cytotoxicity between MCF-7
of P-gp between MCF-7 and MCF-7-Dox cells. Antibody to -tubulin was u
luciferase pMirTarget-MDR1-3= UTR in a dose-dependent manner. The same
pMirTarget-MDR1-3= UTR with deletion of miR-298. D: miR-1253 mimic a
but not on the pMirTarget-vector and pMirTarget-MDR1-3= UTR with dele
mean (C and D).proved cytotoxicity to doxorubicin.The role of miRNAs in mediating chemotherapy resis-
tant mechanisms is relatively new. At present there are
few laboratories, including ours, that study the modula-
tion of P-gp by miRNAs.35,36 On the basis of the pub-
lished reports, there are four miRNAs claimed to be as-
sociated with P-gp-related chemoresistant mechanisms.
Zhu et al36 reported that increased expression of miR-
27a and miR-451 contributes to the MDR and modulates
the expression of P-glycoprotein in human ovarian can-
cer cell line. These investigators showed that transfection
of drug-resistant cells with antagomirs of miR-27a or miR-
451 decreased the expression, suggesting that these two
miRNAs regulate expression of P-gp. In another study,
Kovalchuck et al35 found that low-level expression of
miR-451 is associated with increased expression of
P-gp and doxorubicin chemoresistance of the MCF-7
breast cancer cell line. There are also reports that other
multidrug-resistant proteins (MRP-1 and BCRP/ABCG2)
are also regulated by miRNAs.38,39 In this study, we ex-
amined the role of miR-298, miR-338, miR-1253, and
miR-451 in regulating the expression of P-gp in our MDA-
MB-231-R cells. Among these four miRNAs tested, only
miR-298 expression was confirmed by Northern blot anal-
egulates expression of MDR1-3= UTR chimeric firefly luciferase A: MTT assay
-7-Dox cell lines at 48 hours. B: Western blot analyses show the expression
ading control. C: miR-298 mimic inhibits the expression of chimeric firefly
8 did not regulate the expression of firefly luciferase pMirTarget-vector and
its the expression of pMirTarget-MDR1-3= UTR dose-dependent manner
miR-1253. Data are expressed as mean of triplicated values  SD of thedown-r
and MCF
sed as lo
miR-29
lso inhibysis. We could not detect any other miRNAs reported
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AJP June 2012, Vol. 180, No. 6earlier by Northern Blot analysis. The microRNA-298 has
showed promising results in regulating the expression of
P-gp and increased uptake of doxorubicin and in induc-
ing cytotoxicity. Our results also bring evidence to indi-
cate that the altered expression of miRNA-processing
machinery (Dicer) is significantly altered in the doxorubi-
cin-resistant cell line, leading to improper processing of
miR-298. Our results are also supported by a recent
study indicating that altered expression of miRNA regu-
lators, Drosha and/or Dicer, are associated with a spe-
cific population of triple-negative human breast cancer,
such as the MDA-MB-231 cell line.40 The exact mecha-
nism underlying the effect of altered expression of miR-
298 and P-gp need to be established in the future. In
summary, the results of our study suggest that miR-298 is
a potential marker for identifying chemoresistance of hu-
man breast cancer. We propose that targeted delivery of
miR-298 should reduce the expression of P-gp and im-
prove chemotherapy response of metastatic human
breast cancer.
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